Table 3.

Ongoing clinical studies testing ectonucleotidases and adenosine receptor inhibitors

Trial	Phase	Title	Disease	Intervention	Responsible Party
NCT05177770	Phase 2	Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic castration- resistant prostate cancer	SRF617 (anti-CD39 mAb) AB928 (A2aR/A2bR antagonist) Zimberelimab	Surface Oncology
NCT04381832	Phase 1/2	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)	Castration Resistant Prostate Cancer	AB928 (A2aR/A2bR antagonist) Zimberelimab Quemliclustat (CD73 antagonist) Enzalutamide, Docetaxel Sacituzumab Govitecan	Arcus Biosciences, Inc.
NCT04089553	Phase 2	An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer	Prostate Cancer	AZD4635 (A2aR antagonist) Oleclumab (anti-CD73 mAb) Durvalumab	AstraZeneca
NCT04660812	Phase 1/2	An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer (ARC-9)	Metastatic Colorectal Cancer	AB928 (A2aR/A2bR antagonist) Zimberelimab FOLFOX-6, Bevacizumab Regorafenib Quemliclustat (CD73 antagonist)	Arcus Biosciences, Inc.
NCT03549000	Phase 1	A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.	Advanced Solid Tumors	NZV930 (anti-CD73 mAb) PDR001 NIR178/PBF-509 (A2aR antagonist)	Novartis Pharmaceuticals
NCT03454451	Phase 1	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	Advanced Solid Tumors	CPI-006 (anti-CD73 mAb) Ciforadenant (A2aR antagonist)	Corvus Pharmaceuticals, Inc.